Takeda Canada, Inc. is pleased to announce the approval of DEXILANT (dexlansoprazole), the first and only proton pump inhibitor (PPI) with a novel dual delayed release technology, which delivers two separate doses of medication at different times throughout the day providing improved and sustained symptom relief throughout the day and night. DEXILANT delayed release capsules 30 mg and 60 mg are indicated as a once-daily oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis and the maintenance of healed erosive esophagitis. GERD, a chronic condition commonly known as acid reflux disease, affects one-third of the Canadian population and is often characterized by frequent and persistent heartburn that occurs two or more days a week.
